Biomarkers for Therapeutic Monitoring of Ovarian Cancer

Published date: Aug. 13, 2019

Technology description

A method for assessing therapeutic outcome of a treatment for ovarian cancer comprising determining the amount of one or more proteins in a blood sample from a ovarian cancer patient who is at remission after treatment, wherein the one or more proteins are selected from the group consisting of siCAM1, sTNFR-II, RANTES, sgpl30, MMP-2, CA15-3, MIG, sVCAM-1, TPO, sTNFR-I and MDC and combinations thereof, and wherein elevated serum amounts of the one or more proteins or reduced level of MDC relative to a control indicates that the subject has poor overall survival relative to subjects in remission for ovarian cancer having lower serum amounts of the one or more serum proteins or higher MDC.

Institution

Augusta University

Inventors

Jin-Xiong She
Director
Ctr for Biotechnology & Genomic Med

联系我们

叶先生

电 话：021-65679356
手 机：13414935137
邮 箱：yeyingsheng@zf-ym.com